Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease
Related Experiment Video
Updated: May 13, 2026

Quantifying Spontaneous Ca2+ Fluxes and their Downstream Effects in Primary Mouse Midbrain Neurons
Published on: September 9, 2020
Jonathan W Dickerson1, P Jeffrey Conn
1Vanderbilt University Medical Center, Department of Pharmacology & Center for Neuroscience Drug Discovery, 1205 LH, Nashville, TN 37232, USA.
Abstract:
Parkinson's disease (PD) is a progressive neurological disorder predominantly characterized by motor symptoms including bradykinesia and resting tremor. The gold standard of treatment for PD remains dopamine replacement therapy, which eventually fails due to continued progression of the disease and the development of debilitating side effects. Recent breakthroughs are providing the first major advances in the development of fundamentally new pharmacological strategies for the treatment of PD that do not rely on dopamine replacement strategies, but rather aim to reduce the overactive indirect pathway within the basal ganglia. In this article, we will review the role of metabotropic glutamate receptors within the basal ganglia and discuss the potential for modulation of metabotropic glutamate receptors as a treatment for PD.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Antiepileptic Drugs: Glutamate Antagonists
Ligand-Gated Ion Channel Receptor: Gating Mechanism
